Impact of Stent Deployment Procedural Factors on Long-Term Effectiveness and Safety of Sirolimus-Eluting Stents (Final Results of the Multicenter Prospective STLLR Trial)

      Drug-eluting stent failures were associated with various clinical factors. However, the clinical impact of stent deployment technique was unknown. This study was designed to evaluate the frequency and impact of suboptimal percutaneous coronary intervention on long-term outcomes of 1,557 patients treated with sirolimus-eluting stents (SESs) in 41 US hospitals. All steps of the interventional procedure were scrutinized by an independent core laboratory to determine the occurrence of geographic miss (GM). GM included longitudinal (LGM; injured or diseased segment not covered by SES) or axial GM (balloon-artery size ratio <0.9 or >1.3) mismatches. Patients with and without GM were stratified (GM vs no-GM group). Patients, investigators, and the independent clinical event adjudication committee were blind to study group assignments. The primary end point was 1-year target-vessel revascularization (TVR) rate. Incidences and predictors of GM and safety outcomes were secondary end points. GM occurred in 943 patients (66.5%): 47.6% had LGM, 35.2% had axial GM, and 16.5% had both. One-year TVR rates were 5.1% in the GM group versus 2.5% in the no-GM group (p = 0.025). TVR was 6.1% in the LGM versus 2.6% in the no-LGM subgroups (p = 0.001). The association of GM with 1-year TVR was independent of clinical or anatomic factors (hazard ratio 2.0, 95% confidence interval 1.0 to 4.02, p = 0.05). There was a 3-fold increase in myocardial infarction rates associated with GM (2.4% vs 0.8%; p = 0.04). In conclusion, GM occurred frequently during SES implantation and was associated with increased risk of TVR and myocardial infarction at 1 year. These results emphasized the need for improvement in contemporary percutaneous coronary intervention practices and technologies.
      To read this article in full you will need to make a payment

      References

        • Sabate M.
        • Costa M.A.
        • Kozuma K.
        • Kay I.P.
        • van der Giessen W.J.
        • Coen V.L.
        • Ligthart J.M.
        • Serrano P.
        • Levendag P.C.
        • Serruys P.W.
        Geographic miss: a cause of treatment failure in radio-oncology applied to intracoronary radiation therapy.
        Circulation. 2000; 101: 2467-2471
        • Sianos G.
        • Kay I.P.
        • Costa M.A.
        • Regar E.
        • Kozuma K.
        • de Feyter P.J.
        • Boersma E.
        • Disco C.
        • Serruys P.W.
        Geographical miss during catheter-based intracoronary beta-radiation: incidence and implications in the BRIE Study.
        J Am Coll Cardiol. 2001; 38: 415-420
        • Moses J.W.
        • Leon M.B.
        • Popma J.J.
        • Fitzgerald P.J.
        • Holmes D.R.
        • O'Shaughnessy C.
        • Caputo R.P.
        • Kereiakes D.J.
        • Williams D.O.
        • Teirstein P.S.
        • Jaeger J.L.
        • Kuntz R.E.
        Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery.
        N Engl J Med. 2003; 349: 1315-1323
        • Angiolillo D.J.
        • Sabata M.
        • Alfonso F.
        • Macaya C.
        “Candy wrapper” effect after drug-eluting stent implantation: deja vu or stumbling over the same stone again?.
        Catheter Cardiovasc Interv. 2004; 61: 387-391
        • Urban P.
        • Gershlick A.H.
        • Guagliumi G.
        • Guyon P.
        • Lotan C.
        • Schofer J.
        • Seth A.
        • Sousa J.E.
        • Wijns W.
        • Berge C.
        • Deme M.
        • Stoll H.P.
        Safety of coronary sirolimus-eluting stents in daily clinical practice: one-year follow-up of the e-Cypher registry.
        Circulation. 2006; 113: 1434-1441
        • Costa M.A.
        • Sabate M.
        • Angiolillo D.J.
        • Hu P.
        • Jimenez-Quevedo P.
        • Corros C.
        • Alfonso F.
        • Hernandez-Antolin R.
        • Macaya C.
        • Bass T.A.
        Relocation of minimal luminal diameter after bare metal and drug-eluting stent implantation: incidence and impact on angiographic late loss.
        Catheter Cardiovasc Interv. 2007; 69: 181-188
        • Sabate M.
        • Jimenez-Quevedo P.
        • Angiolillo D.J.
        • Gomez-Hospital J.A.
        • Alfonso F.
        • Hernandez-Antolin R.
        • Goicolea J.
        • Banuelos C.
        • Escaned J.
        • Moreno R.
        • et al.
        Randomized comparison of sirolimus-eluting stent versus standard stent for percutaneous coronary revascularization in diabetic patients: the diabetes and sirolimus-eluting stent (DIABETES) trial.
        Circulation. 2005; 112: 2175-2183
        • Mauri L.
        • Hsieh W.H.
        • Massaro J.M.
        • Ho K.K.
        • D'Agostino R.
        • Cutlip D.E.
        Stent thrombosis in randomized clinical trials of drug-eluting stents.
        N Engl J Med. 2007; 356: 1020-1029
        • Roubin G.S.
        • Douglas Jr., J.S.
        • King III, S.B.
        • Lin S.F.
        • Hutchison N.
        • Thomas R.G.
        • Gruentzig A.R.
        Influence of balloon size on initial success, acute complications, and restenosis after percutaneous transluminal coronary angioplasty.
        Circulation. 1988; 78: 557-565
        • Morice M.C.
        • Serruys P.W.
        • Sousa J.E.
        • Fajadet J.
        • Ban Hayashi E.
        • Perin M.
        • Colombo A.
        • Schuler G.
        • Barragan P.
        • Guagliumi G.
        • Molnar F.
        • Falotico R.
        A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization.
        N Engl J Med. 2002; 346: 1773-1780
        • Sousa J.E.
        • Costa M.A.
        • Abizaid A.C.
        • Rensing B.J.
        • Abizaid A.S.
        • Tanajura L.F.
        • Kozuma K.
        • Van Langenhove G.
        • Sousa A.G.
        • Falotico R.
        • et al.
        Sustained suppression of neointimal proliferation by sirolimus-eluting stents: one-year angiographic and intravascular ultrasound follow-up.
        Circulation. 2001; 104: 2007-2011
        • Morice M.C.
        • Colombo A.
        • Meier B.
        • Serruys P.
        • Tamburino C.
        • Guagliumi G.
        • Sousa E.
        • Stoll H.P.
        Sirolimus- vs paclitaxel-eluting stents in de novo coronary artery lesions: the REALITY trial: a randomized controlled trial.
        JAMA. 2006; 295: 895-904
        • Windecker S.
        • Remondino A.
        • Eberli F.R.
        • Juni P.
        • Raber L.
        • Wenaweser P.
        • Togni M.
        • Billinger M.
        • Tuller D.
        • Seiler C.
        • et al.
        Sirolimus-eluting and paclitaxel-eluting stents for coronary revascularization.
        N Engl J Med. 2005; 353: 653-662
        • Lemos P.A.
        • Saia F.
        • Ligthart J.M.
        • Arampatzis C.A.
        • Sianos G.
        • Tanabe K.
        • Hoye A.
        • Degertekin M.
        • Daemen J.
        • McFadden E.
        • et al.
        Coronary restenosis after sirolimus-eluting stent implantation: morphological description and mechanistic analysis from a consecutive series of cases.
        Circulation. 2003; 108: 257-260
        • Serruys P.W.
        • Kay I.P.
        I like the candy, I hate the wrapper: the (32)P radioactive stent.
        Circulation. 2000; 101: 3-7